Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 6, 2013, Pages 699-706

  Fabi, Alessandra ^a   Merola, Roberta ^a   Ferretti, Gianluigi ^a   Di Benedetto, Anna ^a   Antoniani, Barbara ^a   Ercolani, Cristiana ^a   Nisticò, Cecilia ^a   Papaldo, Paola ^a   Ciccarese, Mariangela ^b   Sperduti, Isabella ^a   Vici, Patrizia ^a   Marino, Mirella ^a   Gori, Stefania ^c   Botti, Claudio ^a   Malaguti, Paola ^a   Cognetti, Francesco ^a   Mottolese, Marcella ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Vito Fazi Hospital   (Italy)

^c SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

EGFR amplification; HER2; HER3; Lapatinib; Metastatic breast cancer

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME 7; DISEASE COURSE; DRUG EFFICACY; DRUG SENSITIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE DOSAGE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; VISCERAL METASTASIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE DOSAGE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REGRESSION ANALYSIS; ROC CURVE;

EID: 84875199261     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.779672     Document Type: Article

References (29)

1. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005;23(19):4265-74
2. . Madarnas Y, Trudeau M, Franek JA, et al.et al. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review. Cancer Treat Rev 2008;34(6):539-57
3. Metro G, Mottolese M, Fabi A. HER-2-positive metastatic breast cancer: Trastuzumab and beyond. Expert Opin Pharmacother 2008;9(15):2583-601
4. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-43
5. Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26(18):2999-3005
6. Liu L, Greger J, Shi H, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL. Cancer Res 2009;69(17):6871-8
7. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112(3):533-43
8. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007;25(22):3238-45
9. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 2005;6(5):279-86
10. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97(9):643-55
11. Szabo B, Nelhubel GA, Karpati A, et al. Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral Oncol 2011;47(6):487-96
12. Gilbert JA, Goetz MP, Reynolds CA, et al. Molecular analysis of metaplastic breast carcinoma: High EGFR copy number via aneusomy. Mol Cancer Ther 2008;7(4):944-51
13. Gumuskaya B, Alper M, Hucumenoglu S, et al. EGFR expression and gene copy number in triple-negative breast carcinoma. Cancer Genet Cytogenet 2010;203(2):222-9
14. Nakajima H, Ishikawa Y, Furuya M, et al. Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer. Breast Cancer 2012; DOI: 10.1007/s12282-012-0354-1
15. Souka E, Alexiadis E, Theohari I, et al. Exon 8 amplification of epidermal growth factor receptor (EGFR) in invasive breast carcinomas. Histopathology 2012;61:644-51
16. Esteva FJ, Yu D, Hung MC, Hortobagyi GN. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 2010;7(2):98-107
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-16
18. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131(1):18-43
19. Han SW, Cha Y, Paquet A, et al. Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer. PLoS One 2012;7(7):e39943
20. Spector NL, Xia W, Burris H, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23(11):2502-12
21. Press MF, Finn RS, Cameron D, et al. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 2008;14(23):7861-70
22. Cappuzzo F, Varella-Garcia M, Finocchiaro G, et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 2008;99(1):83-9
23. Hirsch FR, Varella-Garcia M, Bunn PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21(20):3798-807
24. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007;97(8):1139-45
25. Algars A, Lintunen M, Carpen O, et al. EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer. Br J Cancer 2011;105(2):255-62
26. Toyama T, Yamashita H, Kondo N, et al. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer 2008;8:309
27. Lv N, Xie X, Ge Q, et al. Epidermal growth factor receptor in breast carcinoma: Association between gene copy number and mutations. Diagn Pathol 2011;6:118
28. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366(2):109-19
29. Verma S, Miles D, Gianni L, et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med 2012;367:1783-91